A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body

Summary

The main objective of this trial is to select a formulation and to optimize the identified formulation of BI 685509, if needed.

Conditions

• Healthy

Interventions

DRUG

R1: Reference Product X

under fasted conditions

DRUG

T1: Test Product M

under fasted conditions

DRUG

T2: Test Product N

under fasted conditions

DRUG

T3: Test Product O

under fasted conditions

DRUG

T4: Test Product O

under fed conditions

DRUG

R2: Reference Product Y

under fasted conditions

DRUG

T5: Test Product P

under fasted conditions

DRUG

T6: Test Product P

under fed conditions

DRUG

T7: Test Product Q

under fasted conditions

DRUG

R3: Reference Product Z

under fasted conditions

DRUG

T8: Test Product S

under fasted conditions

DRUG

T9: Test Product S

under fed conditions

DRUG

T10: Test Product U

under fasted conditions

Sponsors & Collaborators

• Boehringer Ingelheim

  lead INDUSTRY

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

MALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-07-01

Primary Completion

2022-02-07

Completion

2022-02-07

FDA Drug

Yes

Countries

• United Kingdom

Study Locations